- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT05417776
Kollagenriktad PET-avbildning för tidig interstitiell lungsjukdom
The goal of this study is to investigate the ability of [68Ga]CBP8 to detect collagen deposition in early interstitial lung disease.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
[68Ga]CBP8, is a PET imaging probe which selectively binds collagen type I. Collagen deposition is a pivotal event in the development of pulmonary fibrosis. [68Ga]CBP8 binds collagen with high affinity and has excellent pharmacological and pharmacokinetic profiles. [68Ga]CBP8 was shown in a mouse model to be effective for detecting lung fibrosis and response to treatment. In addition, [68Ga]CBP8 can detect increased collagen in the lungs of patients with idiopathic pulmonary fibrosis.
The goals of this study are:
- To determine whether collagen deposition as assessed by [68Ga]CBP8-PET MRI can detect increased collagen deposition in early interstitial lung disease and
- if the degree of [68Ga]CBP8 uptake predicts subsequent disease progression.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
Kontakter och platser
Studiekontakt
- Namn: Sydney B Montesi, MD
- Telefonnummer: 617-724-4030
- E-post: sbmontesi@partners.org
Studera Kontakt Backup
- Namn: Abimbola Akinniyi
- Telefonnummer: 781-513-0207
- E-post: aakinniyi@mgb.org
Studieorter
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02114
- Rekrytering
- Massachusetts General Hospital
-
Huvudutredare:
- Sydney Montesi, MD
-
Kontakt:
- Abimbola Akinniyi
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
Group 1: First degree relatives of a family member with pulmonary fibrosis (n=8)
- Age greater than 40 years
- Have the ability to give written informed consent
- First degree relative of a family member with pulmonary fibrosis
- No known history of interstitial lung disease
- No tobacco use within the prior 6 months.
Group 2: Subjects with interstitial lung abnormalities (ILAs) or interstitial lung disease (ILD) (n=22)
- Age greater than 40 years
- Have the ability to give written informed consent
- ILAs or early ILD (defined by presence of reticular markings and / or traction bronchiectasis but absence of a definite UIP pattern)
- No tobacco use within the prior 6 months.
Exclusion criteria:
- Electrical implants such as cardiac pacemaker or perfusion pump
- Ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, metallic tattoos anywhere on the body, tattoos near the eye, or steel implants ferromagnetic objects such as jewelry or metal clips in clothing
- Historical eGFR of less than 30 mL/min/1.73 m2
- Pregnant or breastfeeding (a negative quantitative serum hCG pregnancy test is required for females having child-bearing potential before the subject can participate)
- Claustrophobic reactions
- Research-related radiation exposure exceeds current Radiology Department guidelines (i.e. 50 mSv in the prior 12 months)
- Unable to lie comfortably on a bed inside the MR-PET
- BMI > 33 (limit of the PET-MRI table)
- Determined by the investigator(s) to be clinically unsuitable for the study (e.g. based on screening visit and/or during study procedures)
- Pneumonia or other acute respiratory illness within 6 weeks of study entry
- Parenchymal lung disease except for ILD/ILAs or emphysema
- Acute exacerbation of ILD within the prior 6 months
- VATS within the prior 6 months
- Prior radiation therapy to the thorax
- Known allergy to gadolinium.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Diagnostisk
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Subjects with interstitial lung abnormalities (ILAs) or interstitial lung disease (ILD)
Subjects with interstitial lung abnormalities (ILAs) or interstitial lung disease (ILD) will receive [68Ga]CBP8 and undergo PET-MRI. |
An injection of up to 350 MBq of [68Ga]CBP8 will be administered intravenously followed by PET-MRI. Dotarem will be administered during MRI portion of study.
Andra namn:
|
|
Experimentell: First degree relatives of a family member with pulmonary fibrosis
First degree relatives of a family member with pulmonary fibrosis will receive [68Ga]CBP8 and undergo PET-MRI. |
An injection of up to 350 MBq of [68Ga]CBP8 will be administered intravenously followed by PET-MRI. Dotarem will be administered during MRI portion of study.
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Degree of uptake of [68Ga]CBP8
Tidsram: 24 months
|
The degree of uptake of [68Ga]CBP8 in the lungs will be compared between groups and associations with disease severity and progression will be determined. |
24 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Rate of MRI contrast clearance, Kwashout, in the lungs
Tidsram: 24 months
|
Kwashout rates will be compared between groups and associations with disease severity, progression, and degree of uptake of [68Ga]CBP8 will be determined. |
24 months
|
|
Rate of MRI contrast arrival, Kwashin, in the lungs
Tidsram: 24 months
|
Kwashin rates will be compared between groups and associations with disease severity, progression, and degree of uptake of [68Ga]CBP8 will be determined. |
24 months
|
|
Peak enhancement of MRI contrast in the lungs
Tidsram: 24 months
|
Peak enhancement will be compared between groups and associations with disease severity, progression, and degree of uptake of [68Ga]CBP8 will be determined. |
24 months
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Publikationer och användbara länkar
Allmänna publikationer
- Montesi SB, Izquierdo-Garcia D, Desogere P, Abston E, Liang LL, Digumarthy S, Seethamraju R, Lanuti M, Caravan P, Catana C. Type I Collagen-targeted Positron Emission Tomography Imaging in Idiopathic Pulmonary Fibrosis: First-in-Human Studies. Am J Respir Crit Care Med. 2019 Jul 15;200(2):258-261. doi: 10.1164/rccm.201903-0503LE. No abstract available.
- Desogere P, Tapias LF, Hariri LP, Rotile NJ, Rietz TA, Probst CK, Blasi F, Day H, Mino-Kenudson M, Weinreb P, Violette SM, Fuchs BC, Tager AM, Lanuti M, Caravan P. Type I collagen-targeted PET probe for pulmonary fibrosis detection and staging in preclinical models. Sci Transl Med. 2017 Apr 5;9(384):eaaf4696. doi: 10.1126/scitranslmed.aaf4696.
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 2022P001087
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .